Haemonetics Corp. (NYSE:HAE) plans to lay off about 170 workers and close facilities in Phoenix and Chicago as it integrates its new, $61 million acquisition, GlobalMed Technologies (OTC:GLOB).
Haemonetics Corp. (NYSE HAE) owns about 90 percent of GlobalMed Technologies Inc. this morning, after its extended tender offer for the California-based software provider expired at midnight March 31.
Nearly a year after stepping down as CEO at Haemonetics Corp. (NYSE:HAE), Brad Nutter cashed in another bloc of his holding’s in the blood management firm.
Nutter exercised just more than 173,000 options to purchase Haemonetics stock granted in July 2006 under a long-term incentive program for top executives. The options were priced at $41.15 a share and he promptly the sold the stock for $57 each — a $15.85-per-share profit resulting in net proceeds of nearly $2.75 million.
Haemonetics Corp. (NYSE:HAE) inked a deal with Quotient Biodiagnostics Group subsidiary Alba Bioscience Ltd. that gives it exclusive access to Alba’s portfolio of blood-typing reagents.
The Braintree, Mass.-based blood management products maker will use the reagents for the Arryx laser blood typing platform, which CEO Brian Concannon calls the entry point into a billion-dollar market.
Haemonetics Corp. (NYSE:HAE) extended its offer for GlobalMed Technologies Inc. to give the California-based software provider time to settle a shareholders lawsuit filed to block the acquisition.
Braintree, Mass.-based Haemonetics issued a $1.22-per-share offer, worth about $60 million and set to expire tonight at midnight, for GlobalMed Feb. 1.
The Food & Drug Administration expanded a 510(k) clearance for a Haemonetics Corp. (NYSE:HAE) device used to collect blood.
The Braintree, Mass.-based firm said the FDA expanded its clearance to use its Cymbal automated blood collection system for female blood donors who weigh at least 150 pounds and are 63 inches in height.
Haemonetics Corp. (NYSE:HAE) is expanding its reach into hospital and blood center management, announcing a definitive agreement to pay $60 million for a California-based healthcare software company.
Company executives said the deal — the company’s fourth in less than a year — for GlobalMed Technologies Inc. should significantly expand Haemonetics’ offerings for blood-collection centers with little overlap of its existing business. The acquisition also should broaden Haemonetics’ presence in Europe and Asia, they said.